SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Seeking Alpha / 17 minutes from now 1 Views
Comments